Regulatory Roundup: WHO Releases Draft Guideline For Production And Control Of Specified Starting Materials. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: WHO Releases Draft Guideline For Production And Control Of Specified Starting Materials.

ePT--the Electronic Newsletter of Pharmaceutical Technology

Regulatory Roundup

According to a release from Rx-360, the international pharmaceutical supply-chain consortium, the World Health Organization has released for comment a draft guideline for the production and control of specified starting materials. The draft, currently released to only a specified audience, defines starting materials as “any substance which is primarily or mainly used as a starting material for the production of an API [active pharmaceutical ingredient], but which itself could be used directly as an API” and notes that the specified starting material should therefore “conform to the existing monograph in a recognized pharmacopeia.” If the material is to be used for API production, however, then the “quality attributes and specifications should be determined by the API manufacturer” and the product’s intended use, according to RX-360’s release on the guideline. Quality control for starting materials should include test for impurities, isomers, residual solvents, and other impurities and take a risk-based approach. The consortium has a full summary on its website.

 

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here